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Summary
The Smith-Lemli-Opitz syndrome (SLOS; also known as
“RSH syndrome” [MIM 270400]) is an autosomal re-
cessive multiple malformation syndrome due to a defect
in cholesterol biosynthesis. Children with SLOS have
elevated serum 7-dehydrocholesterol (7-DHC) levels and
typically have low serum cholesterol levels. On the basis
of this biochemical abnormality, it has been proposed
that mutations in the human sterol D7-reductase (7-DHC
reductase; E.C.1.3.1.21) gene cause SLOS. However, one
could also propose a defect in a gene that encodes a
protein necessary for either the expression or normal
function of sterol D7-reductase. We cloned cDNA en-
coding a human sterol D7-reductase (DHCR7) on the
basis of its homology with the sterol D7-reductase from
Arabidopsis thaliana, and we confirmed the enzymatic
function of the human gene product by expression in
SLOS fibroblasts. SLOS fibroblasts transfected with hu-
man sterol D7-reductase cDNA showed a significant re-
duction in 7-DHC levels, compared with those in SLOS
fibroblasts transfected with the vector alone. Using ra-
diation-hybrid mapping, we show that the DHCR7 gene
is encoded at chromosome 11q12-13. To establish that
defects in this gene cause SLOS, we sequenced cDNA
clones from SLOS patients. In three unrelated patients
we have identified four different mutant alleles. Our re-
sults demonstrate both that the cDNA that we have iden-
tified encodes the human sterol D7-reductase and that
mutations in DHCR7 are responsible for at least some
cases of SLOS.
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Introduction
The Smith-Lemli-Opitz syndrome (SLOS; also known as
“RSH syndrome” [MIM 270400]) was first described in
1964 by Smith et al. (1964). Children afflicted with this
syndrome have dysmorphic facial features, mental re-
tardation, hypotonia, poor growth, and variable struc-
tural anomalies of the heart, lungs, brain, gastrointes-
tinal tract, limbs, genitalia, and kidneys (Smith et al.
1964; Gorlin et al. 1990). Elevated levels of 7-dehydro-
cholesterol (7-DHC) are characteristic of this disorder
(Irons et al. 1993; Natowicz and Evans 1994; Tint et
al. 1994; Kelley 1995). The SLOS phenotype can be
variable. Both a “mild” (type I) and a “severe” (type II)
form have been described (Bialer et al. 1987; Curry et
al. 1987; Gorlin et al. 1990). It is thought that both
types represent a spectrum of the same disorder. Children
afflicted with either the type I form or the type II form
have elevated levels of 7-DHC (Tint et al. 1995; Cunniff
et al. 1997). In cholesterol biosynthesis, 7-DHC is con-
verted to cholesterol by the enzyme sterol D7-reductase.
This NADPH-dependent enzyme catalyzes the reduction
of the D7-diene bond in 7-DHC, to form cholesterol.
Liver microsomes from a SLOS homozygote have been
shown to have reduced activity of this enzyme (Shefer
et al. 1995). On the basis of observations of increased
serum 7-DHC, decreased serum cholesterol levels, and
deficient sterol D7-reductase activity, we and others have
hypothesized that the genetic defect causing SLOS is in
the gene encoding the sterol D7-reductase. However, the-
oretically, the genetic defect could also be either in a
cofactor or transporter necessary for sterol D7-reductase
activity or in a transcription factor necessary for efficient
expression of this enzyme.
We report both the cloning of a cDNA that encodes
the human sterol D7-reductase and the identification of
mutant cDNAs in SLOS patients. Human sterol D7-re-
ductase is homologous to a sterol D7-reductase from Ar-
abidopsis thaliana, to fungal sterol D14-reductases, to
fungal sterol D24-reductases, and to the b-lamin receptor
family. The gene encoding sterol D7-reductase maps to
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chromosome 11q12-13. We have identified four separate
mutant alleles from three unrelated SLOS patients. In
one patient, we have identified both mutant alleles, and
another patient may be homozygous for the identified
mutation. Two of the identified mutations are single-base
insertions, and a third is a 134-bp insertion; these in-
sertions introduce frameshifts. The fourth mutation is a
96-bp deletion. To our knowledge, these are the first
reported mutations in SLOS, and identification of these
mutant alleles establishes that mutations in the sterol D7-
reductase gene cause SLOS.
Subjects and Methods
Patients and Cell-Culture Methods
Institutional-review-board approval was obtained for
this research, and informed consent was obtained for
the skin biopsies. The A2SLO and B3SLO cell lines used
in this study were obtained from patients who were clin-
ically diagnosed with SLOS, by R.D.S. and F.D.P. Both
patients had elevated serum 7-DHC levels and were se-
verely affected (type II). Neither had a family history of
consanguinity. One cell line (GM03044) was obtained
from the National Institute of General Medical Sciences
(NIGMS) Human Genetic Mutant Cell Repository. The
available clinical description of this patient is limited;
however, the presence of ambiguous genitalia and di-
agnosis at age 2 wk suggest a severe case of SLOS. El-
evated 7-DHC levels have been found in this cell line.
Control cell lines (GM05659C and GM03468A) were
also obtained from the NIGMS Human Genetic Mutant
Cell Repository. Skin fibroblasts were propagated in
Dulbecco’s minimal Eagle medium and 10% fetal bovine
serum (37C, 5% CO2). Cholesterol-deficient conditions
for growth were created with McCoy’s media supple-
mented with 5% lipoprotein-deficient serum (35 mg pro-
tein/ml, !12 fg cholesterol/ml; PerImmune). SV40 trans-
formation of SLOS fibroblasts was as described
elsewhere (Lei et al. 1992). For expression studies of the
sterol D7-reductase cDNA, the open reading frame of the
DHCR7 gene was amplified by PCR (Clonetech Advan-
tage-HF PCR kit) and was subcloned into pIRES1neo
(Clonetech). SV40-transformed fibroblasts were trans-
fected with Lipofectamine (Gibco BRL) according to the
manufacturer’s protocol. Initial selection of clones was
done with 400 mg G418/ml. Clones were subsequently
maintained in 200 mg G418/ml.
Sterol Analysis of Cell Pellets
The cell pellets were frozen and thawed twice. Lipids
were then extracted as described by Folch et al. (1957).
After saponification and extraction, the TMS derivatives
of the cell sterols were prepared and subjected to gas-
liquid–chromatography analysis (Lin et al. 1993). The
gas-liquid chromatograph (Perkin-Elmer model 8500)
was equipped with a 25-m# 0.32-mm (inner diameter)
CP-WAX-57 CB capillary column (Chrompath). The
temperatures of the column, detector, and injection port
were 210C, 250C, and 250C, respectively. Helium
was used as the carrier gas, and cholestane was used as
an internal standard. Protein content of the samples was
determined by the method of Lowry et al. (1951).
Cloning of the cDNA, and Mutation Analysis
A human EST (IMAGE Consortium Clone ID704713)
was labeled with a[32P]-dCTP, by means of a Boehringer
Mannheim High Prime DNA Labeling Kit. This probe
was then used to screen a Human Liver 5′-Stretch cDNA
library (Clontech). Multiple clones were isolated. Se-
quencing was performed both by means of Amersham
T7 Sequenase version 2.0, with gene-specific primers,
and by automated sequencing on a Pharmacia ALFex-
press using Cy5-labeled M13 universal and reverse prim-
ers. For mutation analysis, reverse transcriptase–PCR
(RT-PCR) (Titan One Tube RT-PCR System; Boehringer
Mannheim) was used to amplify overlapping fragments
of the coding sequence. The mRNA encoding the sterol
D7-reductase was prepared from fibroblasts grown for 7
d in cholesterol-depleted media, by means of a Qiagen
RNeasy Mini Kit. 5′ PCR primers with XbaI ends (5′-
AGTCTAGA-3′) were as follows: HSP1 (5′-TCT AGA
TGG CGT CAC CAA TGA C-3′), HSP3 (5′-CCC AGC
TCT ATA CCT TGT GG-3′), HSP5 (5′-CTT GGC TAT
GCC GTC TCC ACC-3′), HSP7 (5′-CCA TGT GAC
CAA TGC CAT GG-3′), HSP9 (5′-ACC ACC AGA AGG
ACC TGT TC-3′), and HSP11 (5′-TCA ACT ACG TCG
GCG ACC TG-3′). 3′ PCR primers with EcoRI ends (5′-
CGGAATTC-3′) were as follows: HSP2 (5′-ATG GCA
AGA AGT CAG GGA GAG-3′), HSP4 (5′-CTG TGA
AAT TGC AGT CTC TGG-3′), HSP6 (5′-CAT GGC
AGA TGT CAA TGG TC-3′), HSP8 (5′-GTC ATC GAG
TGC TCC TAC AC-3′), HSP10 (5′-TGT AGA AGT
AGG GCA GCA GG-3′), and HSP12 (5′-CCT GGC
AGG AAC ACG CTC TTG-3′). Primer pairs included
HSP1/HSP2, HSP3/HSP4, HSP5/HSP6, HSP7/HSP8,
HSP9/HSP10, HSP11/HSP12, HSP1/HSP8, HSP3/HSP8,
and HSP7/HSP12. The reverse-transcriptase reaction
was done at 50C for 20 min, followed by 10 min at
55C. The PCR-amplification conditions included an in-
itial denaturation at 94C for 2 min; denaturation be-
tween cycles, at 94C for 30 s; annealing steps of 10
cycles at 60C and 25 cycles at 62C; and extension at
68C, as recommended in the Titan RT-PCR protocol.
The PCR products were then subcloned into either
pCR2.1 (Invitrogen), by TA cloning, or pBlueScript SK
(Stratagene). All mutations were confirmed in clones ob-
tained from at least two independent RT-PCR reactions.
Homology analysis was performed by means of BLAST
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Figure 1 Nucleotide and amino acid sequence of clone
pH7DHCR encoding the human sterol D7-reductase. Amino acids that
are identical between the human cDNA and the A. thaliana cDNA
are underlined and are in boldface type. Amino acids that are similar
are gray shaded (BLASTP 2.0.4). A putative polyadenylation signal in
the 3′ UTR is underlined.
computer-based analysis (Altschul et al. 1990, 1997).
Protein sequences were aligned by means of the GCG
Pileup program (Wisconsin Package version 9.1-UNIX).
Radiation-Hybrid Mapping
A GeneBridge 4 radiation hybrid–mapping panel (Re-
search Genetics), which consists of 93 radiation-hybrid
clones, was screened by PCR analysis using primers spe-
cific for theDHCR7 gene. The primer pair (5′-GCC TGG
GCT CCT AAT ACAG-3′ and 5′-CAA GAG CGT GTT
CTG CCA GG-3′) amplified the expected 286-bp frag-
ment of the 3′ UTR, without cross-amplification from
the hamster recipient DNA. The reactions were per-
formed under standard buffer conditions (Perkin Elmer
Cetus) and with 25 mg of hybrid DNA in a 10-ml total
volume. The amplification conditions consisted of an
initial denaturation at 94C for 5 min; followed by 35
cycles of denaturing at 94C for 30 s, annealing at 60C
for 30 s, and extension at 72C for 30 s; and a final
extension at 72C for 5 min. The final PCR products
were separated and visualized on a 1% agarose/ethidium
bromide gel and were scored for the presence or absence
of the appropriate product. The results were confirmed
in a separate set of reactions under identical conditions,
with a second primer pair that amplifies a 167-bp frag-
ment from the coding region (5′-CCC ATC GGC GGA
TAT GTA GG-3′ and 5′-TGC AGC TGT CCA CCC
CGC AC-3′). The results were submitted to the server
at the Whitehead/MIT Center for Genome Research, for
analysis. The computed results were returned and
showed placement of the DHCR7 gene relative to the
framework markers on the radiation-hybrid map. The
result was correlated with the chromosome genetic map,
by identification of markers flanking the DHCR7 locus
that were common to both maps. The cytogenetic po-
sition of the locus was then inferred from the genetic
map, given the relative physical positions of the flanking
markers.
Results
On the basis of the predicted amino acid sequence of
an A. thaliana enzyme that encodes a sterol D7-reductase
activity (Lecain et al. 1996), we cloned, by homology,
a cDNA that encodes the human sterol D7-reductase. The
predicted amino acid sequence of the plant enzyme was
used to identify a human expressed sequence tag (EST)
(AA282412, tonsillar B-lymphocytes; IMAGE Consor-
tium clone ID704713) that had significant homology.
We used this human EST to isolate longer cDNA clones
from a human liver library. The longest cDNA clone
that we isolated was 1,852 nucleotides in length and
encoded a 417-amino-acid open reading frame (fig. 1).
This cDNA clone is truncated at an internal XbaI re-
striction site. Thus, the mRNA potentially encodes a
longer peptide. At the amino acid level, the predicted
protein has 37% identity and 55% similarity (BLASTP
2.0.4; Altschul et al. 1997) to the A. thaliana enzyme.
Although the highest sequence homology was found
with the functionally similar A. thaliana sterol D7-re-
ductase, the predicted peptide also has significant ho-
mology to fungal sterol D14-reductases (GenBank acces-
sion numbers Y10624, S30769, S44170, and X94315),
to the carboxyl-terminal portions of the human and rat
b-lamin receptors (GenBank accession numbers L25941
and AB002466), and to fungal sterol D24-reductases
(GenBank accession numbers S64014 and A43765) (fig.
1, and data not shown). Neither the human nor the plant
sterol D7-reductase has the EFGGXXG motif conserved
in the sterol D14-reductases, in the sterol D24-reductases,
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Figure 2 Northern blot analysis comparing expression of the
human sterol D7-reductase mRNA from fibroblasts grown with fetal
bovine serum (), compared with fibroblasts grown in lipoprotein-
deficient serum (). A 7.5-mg sample of total RNA was loaded in each
lane. The DHCR7 transcript is ∼4 kb. Equivalent loading of samples
was confirmed by means of a probe to human GADPH (data not
shown).
and in the b-lamin receptors (Lecain et al. 1996). Thus,
on the basis of homology, this gene likely encodes the
human sterol D7-reductase. While the manuscript of this
article was in preparation, Moebius et al. (1998) re-
ported an independent cloning of this gene. They showed
the presence of sterol D7-reductase activity when this
gene was expressed in Saccharomyces cerevisiae. Mu-
tational analysis in SLOS was not reported. This work
provides further conformation that this cDNA that we
identified encodes human sterol D7-reductase.
Cholesterol biosynthesis in cells is highly regulated,
and transcription of cholesterol biosynthetic enzymes is
down-regulated when exogenous LDL cholesterol is
available. Using northern blot analysis, we compared the
expression of the human sterol D7-reductase in fibro-
blasts grown with and without an exogenous source of
LDL cholesterol. Consistent with an enzyme involved in
cholesterol biosynthesis, the mRNA encoding this pro-
tein is induced when fibroblasts are grown in LDL cho-
lesterol–deficient media (fig. 2). No marked differences
were observed between control lines and SLOS lines (fig.
2, and data not shown).
To prove that this cDNA encodes a sterol D7-reduc-
tase, we cloned this cDNA into an expression vector,
pIRES1neo, and stably transfected this construct into
two SV40-transformed SLOS fibroblast lines (A2SLO-T
and B3SLO-T). This vector (pIRES1neo8) constitutively
expresses the putative sterol D7-reductase cDNA, under
control of the human cytomegalovirus major, immediate,
early promotor/enhancer. Using gas chromatography, we
measured sterol levels in cell lines expressing the sterol
D7-reductase cDNA, and we compared these levels with
levels of 7-DHC in cell lines transfected with the vector
alone. After 5 d of growth in lipoprotein-deficient serum,
cholesterol levels increased to 166% of control levels,
and 7-DHC levels decreased to 45% of control levels
(table 1). The 7-DHC/cholesterol and 7-DHC/total-
sterol ratios were decreased, respectively, to 26% and
38% of control levels. In a similar experiment, with the
B3SLO cell line, the 7-DHC/cholesterol and 7-DHC/to-
tal-sterol ratios were decreased, respectively, to 52% and
65% of control levels ( ). The variability betweenP ! .005
cell lines is likely due to the use of pools of transfected
cells. These results prove that the human cDNA isolated
by homology to theA. thalianaD7-reductase functionally
encodes a sterol D7-reductase.
We used radiation-hybrid mapping to learn the chro-
mosomal location of the human sterol D7-reductase gene.
The data vector resulting from screening the radiation-
mapping panel was 10010 00001 00000 10011 00000
00110 00000 10001 01001 10000 00100 00000 01001
00011 00110 00001 11001 00000 001. Interpretation
of these data from the radiation-hybrid map placed the
DHCR7 gene 2.33 cR3000 from GCT16B07 on chro-
mosome 11, linking it, at a LOD score of 19, with
D11S913 and D11S916. The position of DHCR7 rel-
ative to both the radiation-hybrid map and the corre-
sponding genetic and cytogenetic maps is shown in figure
3. Given its position between D11S913 and D11S916
on the radiation-hybrid map, DHCR7 can be assigned
a placement 70.9–80.1 cM from the top of the genetic
map of chromosome 11. Cytogenetically, it is therefore
likely that the DHCR7 locus is in the 11q12-13 interval.
To determine whether mutations in the human sterol
D7-reductase gene cause SLOS, we used RT-PCR to sub-
clone overlapping segments of cDNA from SLOS fibro-
blasts. Sequence analysis of these cDNAs allowed us to
identify four mutations in three unrelated patients (table
2). A 134-bp insertion (figs. 1 [nucleotide 788/789] and
4A) was identified in the A2SLO cell line. This insertion
results in a frameshift, starting at amino acid 263, that
precludes translation of the highly conserved carboxyl
end of the protein. This cell line may be homozygous
for this insertion. Of seven cDNA clones sequenced from
this region, all had the 134-bp insertion ( ).P ! .01
Northern blot analysis showed the presence of a slightly
larger transcript in mRNA from the A2SLO cell line (fig.
4B). Finally, PCR analysis of this region demonstrated
the presence of a single larger product in A2SLO samples
(fig. 4C). A normal-size allele was not observed. Four
separate primer pairs (HSP3/HSP8, HSP5/HSP8, HSP7/
HSP8, and HSP7/HSP10) that flank this region gave sim-
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Figure 3 DHCR7 locus integrated into the radiation-hybridmap
of human chromosome 11, with correlation to the genetic and cyto-
genetic maps. Numbers to the right of the radiation hybrid and genetic
maps indicate distances from the top of the maps, in cR3000 and cM,
respectively. The inferred position of the DHCR7 gene at 11q12-13
is indicated by the bar to the left of the ideogram.
Table 1
Sterol Analysis in A2SLO Fibroblasts Expressing Human Sterol D7-Reductase cDNA
VECTOR
MEAN  SDa
Cholesterol
(mg sterol/mg cellular protein)
7-DHC
(mg sterol/mg cellular protein)
Total Sterol
(mg sterol/mg cellular protein) 7-DHC/Cholesterol
pIRES1neo 7.03 1.40 5.84 1.13 14.05 2.67 .83 .06
pIRES1neo8 b11.66 .78 b2.63 1.64 15.32 2.59 b.22 .12
NOTE.—Stably transfected cell lines were grown for 5 d in lipoprotein-deficient media. Sterol analysis of the cell pellets was done by
gas chromatography.
a Of three samples.
b , by Student’s paired t-test.P ! .02
ilar results (data not shown). Thus, our sequencing,
northern blot, and PCR data are consistent with the
presence of a homozygous mutant allele. Alternatively,
a second allele could be untranscribed or could give rise
to an unstable transcript that is not detectable by either
RT-PCR or northern blot analysis.
Both mutant alleles were identified in a second SLOS
patient (B3SLO). One mutation is a 96-bp deletion (fig.
1, nucleotides 77 to 19). This mutation potentially
removes the start codon. Neither of the two ATGs pres-
ent in the undeleted 5′ region are in-frame, and the next
in-frame ATG encodes amino acid 138. If the initiation
codon is 5′ of the XbaI site, then this mutation would
result in both the removal of 32 amino acids from the
amino terminus of this enzyme and introduction of a
cysteine residue. Consistent with the autosomal recessive
nature of this disorder, this patient has a second mutant
allele. The second allele has a single cytosine insertion
between nucleotides 505 and 506. This insertion results
in both a frameshift starting at amino acid 170 and
addition of 39 aberrant amino acids.
A fourth mutation was also identified in the C4SLO
cell line. This mutation is a single thymidine insertion
between nucleotides 586 and 587. The result of this
insertion is both a frameshift starting at amino acid 197
and the addition of 12 aberrant amino acids. We have
not yet identified the second mutation in this cell line.
Both the single-base insertions in B3SLO and C4SLO
would preclude normal translation of the highly con-
served carboxyl-terminal half of this protein.
Discussion
The human sterol D7-reductase catalyzes the reduction
of the D7-diene bond in 7-DHC, to form cholesterol.
Children with SLOS have elevated serum levels of 7-
DHC and often have low serum cholesterol levels, and
cells from these patients have decreased sterol D7-reduc-
tase activity. On the basis of these observations, it had
been proposed that SLOS is the result of a defect in
cholesterol biosynthesis. A defect in cholesterol biosyn-
thesis can readily explain the low cholesterol levels and
high 7-DHC levels in blood and tissues, abnormal bile
acid profiles, hepatic failure, growth failure, genital hy-
poplasia, and hypomyelination seen in this disorder. The
relationship between a defect in cholesterol biosynthesis
and the developmental malformations that also char-
acterize this disorder was initially more difficult to ex-
plain. However, it is now known that sonic hedgehog
(shh), a morphogen involved in patterning the CNS and
limbs, is anchored to the plasma membrane via a co-
valent bond with cholesterol (Porter et al. 1996a,
1996b). Thus, shh function may be impaired in SLOS,
because of either cholesterol deficiency or the presence
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Table 2
Mutations of Human Sterol H7-Reductase, Identified
in SLOS
Patient SLO Type Mutation
Nucleotide
Position
A2SLO II 134-bp insertion 788/789
B3SLO II C insertion 507/508
96-bp deletion 77 to 19
C4SLO IIa T insertion 587/588
a Available clinical description is limited.
Figure 4 134-bp insertion in A2SLO. A, Nucleotide sequence
and predicted amino acid sequence of the mutant allele. The normal
nucleotide sequence is in uppercase letters, and the inserted sequence
is in lowercase letters. Aberrant amino acids are in lowercase letters.
B, Northern blot analysis of sterol D7-reductase transcript from control
and SLOS fibroblasts. The transcript from the A2SLO cell line is
slightly larger. C, Ethidium bromide–stained gel of PCR products from
control (lanes 1 and 2), A2SLO, and B3SLO cell lines. The expected
605-bp product was found in the control and B3SLO cell lines. A
single aberrant 739-bp fragment was found in the A2SLO sample.
of high levels of 7-DHC. Consistent with this idea, the
shh-mutant mouse has phenotypic overlap with severe
SLOS (Chiang et al. 1996). In addition, pharmacological
inhibitors of sterol D7-reductase are teratogenic, and rat
embryos exposed to these inhibitors have phenotypic
overlap with both severe SLOS and the shh-mutant
mouse (Roux et al. 1980; Dehart et al. 1997).
Given the observed biochemical defect of deficient
sterol D7-reductase activity, we and others had hypoth-
esized that the genetic defect would be in the gene en-
coding this enzyme. However, it was also possible that
the genetic defect could be in a cofactor of this enzyme,
a transporter necessary for sterol D7-reductase activity,
or in a transcription factor necessary for normal ex-
pression of this enzyme. To answer this question, we
have cloned a cDNA encoding a human sterol D7-re-
ductase. This cDNA encodes a 417-amino-acid open
reading frame. Our cDNA is truncated at an internal
XbaI site. Thus, it is possible that the mRNA encodes
a longer peptide. A longer open reading frame, of 475
amino acids, has been reported by Moebius et al. (1998).
The plant sterol D7-reductase has an open reading frame
of 430 amino acids; and the homology between the plant
and human genes is poor in this area. However, the
amino terminus predicted by the previous clone is in-
frame with the peptide predicted by our cDNA. Thus,
the 5′ UTR depicted in figure 1 may be translated. Func-
tionally, our fibroblast expression studies clearly dem-
onstrate both that our cDNA encodes a functional sterol
D7-reductase and that the potential initiation codon that
we have identified functions in human fibroblasts. De-
termination of the actual initiation codon will require
analysis of coupled transcription-translation products
and of the native protein. The predicted protein sequence
is highly homologous to other sterol reductases. The
highest homology was found with the A. thaliana sterol
D7-reductase. In addition, like the plant sterol D7-reduc-
tase, the human enzyme does not encode an EFGGXXG
motif that is found in other members of the sterol re-
ductase family.
Cells acquire the cholesterol that they need either from
dietary cholesterol or by endogenous biosynthesis of
cholesterol. This is a tightly regulated process. If exog-
enous LDL cholesterol is available, endogenous biosyn-
thesis of cholesterol is down-regulated. Using northern
blot analysis, we looked at the expression levels of the
mRNA encoding the human sterol D7-reductase from
cells grown with and without an exogenous source of
cholesterol. As we expected, the mRNA encoding this
enzyme was up-regulated when fibroblasts were grown
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in cholesterol-deficient media. To prove functionally that
this cDNA encodes an enzyme with sterol D7-reductase
activity, we expressed this cDNA in SLOS fibroblasts.
Stable expression of this cDNA resulted in a significant
reduction in 7-DHC levels. Thus, on the basis of both
homology and function, we have identified a human
sterol D7-reductase.
Using radiation-hybrid mapping, we have established
that the human sterol D7-reductase maps to chromosome
11q12-13. Previously, it had been reported that SLOS
syndrome maps to chromosome 7q32.1 (Alley et al.
1995). This was based on the finding of a similar trans-
location in one biochemically confirmed case of SLOS
and one historical case of SLOS (Curry et al. 1987). A
second historical case of SLOS had a chromosomal
translocation involving chromosome 7q34 (Berry et al.
1989). Further analysis of the breakpoint region showed
that the disrupted region encodes a metabotropic glu-
tamate receptor (Scherer et al. 1997). Thus, for a chro-
mosomal translocation in that region to cause an au-
tosomal recessive disorder such as SLOS, one must
propose both a long-range effect on the expression of
one allele and an independent mutation in the second
allele. We propose that these previous reports represent
an unrelated coincidence of similar chromosomal trans-
locations in SLOS patients. Alternatively, locus hetero-
geneity could exist for this disorder.
To establish that mutations in the human sterol D7-
reductase gene cause SLOS, we sequenced cDNA clones
from three unrelated SLOS type II patients. We have
identified four different mutant alleles from these pa-
tients (table 2). Because SLOS is an autosomal recessive
disorder, the identification of mutations in both alleles
is necessary for establishing that mutations in this gene
cause SLOS. In B3SLO we have identified mutations in
both alleles. One is a deletion of 96 nucleotides, and the
second is a single cytosine insertion between nucleotides
505 and 506. This 96-nucleotide deletion has not been
observed in cDNA clones either from control cells or
from other SLOS cell lines. Thus, this deletion is unlikely
to represent a normal splice variant. In A2SLO, we iden-
tified a 134-bp insertion. Using sequence analysis, RT-
PCR, and northern blot analysis, we could not detect a
second allele. Thus, A2SLO may be homozygous for this
mutation. A fourth mutant allele was identified in a third
patient (C4SLO). This mutant allele has a single thy-
midine insertion between nucleotides 586 and 587. The
SLOS mutant alleles reported in this paper all come from
severely affected patients and are predicted to result in
a severe disruption of the sterol D7-reductase. Although
further genotype/phenotype correlation is necessary, this
may explain the severe phenotype seen in these patients.
It is possible that milder cases of SLOS are due to mu-
tations in another gene. However, we propose that mu-
tations that do not preclude translation of the highly
conserved carboxyl half of this enzyme—mutations such
as missense changes—may cause milder cases of SLOS.
The data presented here demonstrate that we have
cloned a cDNA encoding the human sterol D7-reductase.
This conclusion is based on significant homology to an
A. thaliana sterol D7-reductase, induction of the mRNA-
encoding enzyme by growth in cholesterol-deficient me-
dia, and functional correction of the biochemical defect
in SLOS fibroblasts transfected with this cDNA. Fur-
thermore, we have identified four different mutations in
this gene in three unrelated SLOS patients. In one of
these patients we have identified two mutant alleles, and
a second patient may be homozygous for the identified
mutation. Thus, we conclude that mutations in the hu-
man sterol-D7-reductase gene cause at least some cases
of SLOS.
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